Contineum Therapeutics shares exploded higher during the regular session, likely benefiting from a wave of positive sentiment across the biotechnology sector. The broader industry saw significant momentum on September 30, 2026, driven by major positive Phase 2 clinical data from Connect Biopharma regarding its COPD treatment, which reported an 85% decrease in moderate to severe exacerbations. While there is no company-specific news for Contineum, the stock participated in a sector-wide rally as investors reacted to these high-profile clinical developments and a new FDA initiative aimed at expanding scientific expertise within its advisory committees.